Open-label, Non-Randomised Extension Trial to Assess the Long-Term Safety and Efficacy of 1200 mg/day Arimoclomol Citrate 400 mg Three Times a Day (t.i.d.) in Subjects with Amyotrophic Lateral Sclerosis (ALS) who have Completed the ORARIALS-01 Trial (NCT03836716)

Primary Investigator: Matthew Elliott

Clinical Research Coordinator: Mary Wagoner

A Multicenter Phase IIb Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane (NCT04028388)

Primary Investigator: Robert Dreicer

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (NCT03657160)

Primary Investigator: Leonid Volodin

Clinical Research Coordinator: Megan Healy

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Primary Investigator: Laahn Foster

Clinial Research Coordinator: Sharon Johnson

A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness (NCT03770403)

Primary Investigator: Sarah Jones

Clinical Research Coordinator: Mary Wagoner

Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia (NCT03258931)

Primary Investigator: Michael Keng

A Phase II trial of sEphB4-HSA in combination with ANti PD1 Antibody Pembrolizumab (MK-3475) for metastatic urothelial cancer refractory to platinum. (NCT02717156)

Primary Investigator: Michael Devitt

Clinical Research Coordinator: Jennifer Drake

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (NCT03657160)

Primary Investigator: Leonid Volodin

Clinical Research Coordinator: Megan Healy

Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320)

Primary Investigator: Lynn Dengel

Clinical Research Coordinator: Rachael Reed

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies (NCT02730299)

Primary Investigator: Leonid Volodin

Phase I Study of Inotuzumab Ozogamicin with 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Younger Adults Ages 18-55 with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03962465)

Primary Investigator: Michael Douvas

Clinical Research Coordinator: Cara Hanby

A Phase Ib/2, Open-Label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-Line Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (COLUMBIA-1) (NCT04068610)

Primary Investigator: Matthew Reilley

Clinical Research Coordinator: Sallie Mannen

COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Therapy for Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Stage I-III Breast Cancer (NCT04038489)

Primary Investigator: Patrick Dillon

Clinical Research Coordinator: Jake Boyd

Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age. PrECOG Protocol Number: PrE0405. (NCT03834688)

Primary Investigator: Craig Portell

Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer (NCT03989362)

Primary Investigator: Ryan Gentzler

Clinical Research Coordinator: Gracie Hockenberry

A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) (NCT03971474)

Primary Investigator: Richard Hall

Clinical Research Coordinator: Gracie Hockenberry